{"pub": "afr", "url": "https://afr.com/companies/healthcare-and-fitness/clinuvel-pharmaceuticals-gets-fda-tick-surges-36-pct-20191009-p52yyy", "downloaded_at": "2019-10-09 02:12:20.979923+00:00", "title": "Clinuvel Pharmaceuticals gets FDA tick, surges 36pc", "language": "en", "text": "Shares in Clinuvel Pharmaceuticals have surged by as much as 36 per cent in early trade as the biotech gained a tick of approval by the powerful US Food & Drug Administration to use its drug Scenesse for the treatment of patients in the United States.\n\nClinuvel has been seeking FDA approval for its drug to treat a rare skin disease that causes extreme light sensitivity, and is among the market's best performers.\n\nIt was inducted to the ASX 200 this year and its share price has climbed more than 80- per cent in the past 12 months, peaking at $38.95 in mid-June. Its market value has ballooned to nearly $1.7 billion - making it a similar size company to rare earths miner Lynas Corp.\n\nClinuvel chief executive Dr Philippe Wolgen is the company's second largest shareholder. Supplied\n\nShares in Clinuvel surged in early trade Wednesday as high as $42.38 each - a fresh 52 week high -but by 11.15 am eastern Australian time were trading up 27.4 per cent to $39.95.\n\nScenesse activates the production of melanin \u2013 the skin's natural defence against ultra-violet light \u2013 to protect patients against sun-related diseases. It is used to treat erythropoietic protoporphyria (EPP) \u2013 a rare genetic disorder that causes burns after brief exposure to light.", "description": "Clinuvel has been seeking FDA approval for its drug to treat a rare skin disease that causes extreme light sensitivity, and is among the market's best performers.", "authors": [], "top_image": "https://static.ffx.io/images/$zoom_1.1099%2C$multiply_0.7554%2C$ratio_1.777778%2C$width_1059%2C$x_0%2C$y_31/t_crop_custom/e_sharpen:25%2Cq_85%2Cf_auto/0bfeb4e1fc1aabc9168339e66acf5cb44514ea40", "published_at": "2019-10-09"}